You are here » Home » Companies » Company Overview » Dr Lal Pathlabs Ltd

Dr Lal Pathlabs Ltd.

BSE: 539524 Sector: Health care
NSE: LALPATHLAB ISIN Code: INE600L01024
BSE 00:00 | 30 Sep 2521.35 -70.95
(-2.74%)
OPEN

2561.85

HIGH

2602.95

LOW

2509.90

NSE 00:00 | 30 Sep 2518.75 -72.65
(-2.80%)
OPEN

2580.10

HIGH

2610.00

LOW

2508.35

OPEN 2561.85
PREVIOUS CLOSE 2592.30
VOLUME 13548
52-Week high 3943.95
52-Week low 1805.10
P/E 69.96
Mkt Cap.(Rs cr) 21,015
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 2561.85
CLOSE 2592.30
VOLUME 13548
52-Week high 3943.95
52-Week low 1805.10
P/E 69.96
Mkt Cap.(Rs cr) 21,015
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Dr Lal Pathlabs Ltd. (LALPATHLAB) - Chairman Speech

Company chairman speech

Dear Shareholders

We are happy to announce a successful conclusion to FY22. Dr. LalPathLabs maintained its track record of being India's leading diagnostics lab chainproviding the best quality diagnostic services to patients in an affordable and accessiblemanner.

I n a significant development during FY22 we strengthened our presencein the fast-growing region of Western India by the acquisition of Suburban DiagnosticsMumbai. While this will vastly improve our business in this region the objective is toleverage the expertise of both the companies to deliver accurate diagnostics with betterpatient experience. Thus the acquisition of Suburban Diagnostics will help us establish astrong base in the high-growth region of Western India in-line with our strategy. Alsoour hub-and-spoke business model spread across India has been very effective andefficient in helping us reach and penetrate deeper. With our well-established RegionalReference Labs in North and East India giving us healthy increment in patient volumes. Wealso remain on track to acquire smaller unbranded labs across the country through oursubsidiary PathLabs Unifiers Private Limited.

The year FY22 was marked by sharp recovery in the non-COVID businesspost two successive COVID-19 waves. The year began with a nation-wide lockdown beingimposed on account of the second wave of the COVID-19 pandemic which was more severe thanthe first one. The morbidity and mortality from this Delta virus were more this time.After the second wave receded the caseloads stayed well under control until December dueto the rapid vaccination drive when the new and fast-transmitting Omicron variant startedspreading. However fortunately it was not very resurgent and died down soon after. Dr.Lal PathLabs remained at the forefront providing quality and efficiency in COVID andallied testing throughout the year and especially during these two periods. One keychange that we witnessed since the onset of the pandemic was that home collections andonline bookings were the most preferred options used by the patients.

The scope for growth in the Indian healthcare industry especially thediagnostics industry is considerable. India continues to have a significantly lowerhealthcare expenditure as a percentage of GDP as compared to many other nations. Moreoverthe shift of market share from the unorganized to the organized sector in the industry hasbeen rapid since the onset of the pandemic. To reap the benefits of this trend Dr. LalPathLabs has been making use of technology to improve efficiency and experience ofservices for the patients.

The shift in industry trends wherein the market share moving from theunorganized to the organized sector has accelerated. Consumers prefer the assurance ofquality and efficiency offered by a branded pan-India player something that unorganizedplayers cannot offer. Also post the pandemic people have become more attentive to theirhealth. By consistently addressing these concerns Dr. Lal PathLabs has maintained itsposition as a leading diagnostics player in India with growing presence in newer regions.

Government of India (GoI) has announced various initiatives and hasalso increased spending across several schemes so that healthcare benefits reach more andmore people in India. In the FY22-__ Union Budget GoI continues to adopt policies gearedtowards developing a resilient healthcare system in the country. The Department of Healthand Family Welfare has been allocated Rs 83000 crore including an allocation of Rs 6412crore for the flagship Ayushman Bharat Pradhan Mantri Jan Aarogya Yojana. Theseinitiatives undertaken by the Government in the healthcare space in the last few years hasbeen heartening and gives us great confidence in the scope for growth in the Indianhealthcare industry.

We continue to drive our business on the back of high patient volumesand favorable test mix. We have been able to grow our volumes consistently through theyears without compromising on our margins nor increasing prices of the tests. Thisgrowth in topline and profitability has ensured that Dr. Lal PathLabs remains a leadingplayer in the industry with a bigger footprint. There is a vast opportunity in the Indiandiagnostics space and we are very well positioned to leverage it.

Lastly I would like to extend my deepest gratitude to all ourstakeholders including investors associates vendors patients customers andemployees who have supported us throughout our journey and placed their trust in ourbrand. We will continue to strive to bring the best quality diagnostics to our patientsand value to our investors.

Warm regards
(Hony) Brig. Dr. Arvind Lal Padma Shri
Executive Chairman

.